{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse.00706:a retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahse.00706%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.010108,
    "timestamp_received": "2026-04-25T14:11:05.558810+00:00Z",
    "timestamp_returned": "2026-04-25T14:11:05.568918+00:00Z",
    "trace_id": "19bb26e6-2d9d-44db-931d-814dc425136b"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:hse.00706:a",
      "indication": "Pembrolizumab is indicated, in combination with CISplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS >= 1.",
      "initial_approval_date": "2021-12-20",
      "initial_approval_url": null,
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with cisplatin and 5-fluorouracil for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 with a CPS >= 1.",
      "raw_biomarkers": null,
      "raw_cancer_type": "head and neck squamous cell carcinoma",
      "raw_therapeutics": "Pembrolizumab in combination with cisplatin and 5-fluorouracil",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hse.00706",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Pembrolizumab, Cisplatin and 5-Fluorouracil Therapy. NCCP National SACT Regimen. HSE.",
        "title": null,
        "aliases": [],
        "description": "Pembrolizumab, Cisplatin and 5-Fluorouracil Therapy, 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6880/706_V3_Pembrolizumab_CISplatin_5FU_.pdf",
        "urls": [
          "https://healthservice.hse.ie/documents/6880/706_V3_Pembrolizumab_CISplatin_5FU_.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hse",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Service Executive",
              "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": null,
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": null,
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": null,
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2023-04-26",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}